@article{77c12629ab334293b0b72c3761d048e2,
title = "STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure",
abstract = "B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.",
keywords = "B-type natriuretic peptide, STOP-HF Trial, heart failure, rs198389, single nucleotide polymorphism",
author = "Valentina Cannone and Mark Ledwidge and Chris Watson and McKie, {Paul M.} and Burnett, {John C.} and Kenneth McDonald",
note = "Funding Information: This study was supported by the Circulatory Failure Research Award from the Circulatory Failure Division, Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota, USA; Health Research Board (HRB) Ireland Awards POR 2012/119 and CSA 2012/36; and a grant from the National Institutes of Health (HL 136340-04). Dr McDonald has received consultancy fees from Novartis. Drs McDonald and Ledwidge have received funds from Novartis for the PARABLE trial. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = jun,
doi = "10.1016/j.jacbts.2021.05.001",
language = "English (US)",
volume = "6",
pages = "497--504",
journal = "JACC: Basic to Translational Science",
issn = "2452-302X",
publisher = "Elsevier Inc.",
number = "6",
}